



NextGen Sciences Strengthens Protein Biomarker Team with Two Key Appointments

Ann Arbor, MICHIGAN, May19 2008 - NextGen Group plc, (AIM: NGG), a provider of biomarker testing services, has announced the expansion of its protein biomarker team with the appointment of Dr. Ruth VanBogelen as Director of Biomarkers and Proteomics and Dr. M. Walid Qoronfleh as Vice President of Business Development. These appointments are part of the Group's strategy to focus resources on growing the biomarker service business to meet the needs of its customers.

Launched in November 2007, NextGen Sciences' service portfolio (**biomarkerexpress™**) includes biomarker discovery, assay development and testing. The suite of services includes proprietary methods to enable biopharma clients, researchers and clinicians to select the best biomarkers for each Research and Development program, and for use in predictive medicine. The Company is currently running a number of biomarker projects in therapeutic areas including oncology and Alzheimer's disease, which are nearing delivery.

Dr. VanBogelen joins NextGen Sciences from Pfizer, Inc., where she was Director of Proteomics for Research and Development. She has thirty years of experience using proteomics technologies to generate and test hypotheses for pre-clinical and clinical programs in both industry and academia. Prior to Pfizer (and Warner-Lambert) she lead research into microbial proteomics at the University of Michigan Medical Center. Dr. VanBogelen has published over 30 peer-reviewed scientific papers and has authored numerous review articles and book chapters on proteomics. She currently serves on the Editorial Board for the journals Proteomics, Proteomics Clinical Applications and the Journal of Proteomics and Bioinformatics.

Dr. Walid Qoronfleh joins NextGen Sciences from the successful Q3 Consulting Group where he was a founder and Managing Director. With over 20 years of commercial experience, Walid has held various senior management and executive positions at AntexPharma, Pierce Biotechnology (now part of ThermoFisher) and CTA Corp/University of Michigan-Ann Arbor. Walid's previous scientific, R&D and technology appointments include SmithKline Beecham (now GlaxoSmithKline), Sterling-Winthrop Pharmaceuticals (now part of Sanofi-Aventis) and the National Cancer Institute. Walid received an MBA from Penn State University as well as a Marketing certificate from the University of Wisconsin-Madison.

Commenting on the appointments, Dr. Mike Pisano, CEO of NextGen Sciences, said: "I am delighted to welcome Ruth and Walid to the team. Ruth's leadership, knowledge and vision will help us focus our biomarker and proteomics services towards the evolving needs of the pharmaceutical industry. Walid's extensive commercial experience in the pharmaceutical sector will support the continued growth of our Biomarker Service business."

- ENDS -

For high-resolution images please contact College Hill



Dr. Ruth VanBogelen



Dr. Walid Qoronfleh

Notes to Editors

NextGen

NextGen Group PLC (AIM: NGG) is a provider of biomarker services for pharmaceutical and biotech companies globally. Using advanced techniques, such as Multiple Reaction Monitoring (MRM) mass spectrometry analysis, the Company is developing a portfolio of robust assays for testing clinical samples for drug safety and efficacy, and the development of personalised treatment for patients.

Headquartered in Ann Arbor, Michigan, NextGen's range of services, which include biomarker testing, discovery and assay development, are employed by its customers as a key part of the biomarker-based drug and diagnostic development process.

Contact:

College Hill

Lorna Cuddon, Katie Odgaard, Benjamyn Tan

T: +44 (0)20 7457 2020

E: nextgen@collegehill.com